The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...
Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...